IL6R and rheumatoid arthritis: Considering that JAK inhibitors baricitinib and upadacitinib, as well as the IL-6R inhibitor sarilumab, have been recently approved by the FDA for RA treatment, an insight into these novel therapeutic agents seems to be in order.